PEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against PepGen, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product PGN-EDO51 during the class period from March 7, 2024, to March 3, 2025 [1][3]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Eastern District of New York on behalf of all individuals and entities who purchased PepGen securities during the specified class period [1]. - Investors have until August 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against PepGen - The complaint alleges that PepGen's management made false and misleading statements about the effectiveness and safety of PGN-EDO51 [3]. - It is claimed that the CONNECT2 study was either dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating PGN-EDO51's clinical, regulatory, and commercial prospects [3]. Investor Information - Investors who suffered losses or have questions regarding the lawsuit are encouraged to contact the law firm Bragar Eagel & Squire for more information [4].